[go: up one dir, main page]

JO3096B1 - الأجسام المضادة لمستقبل ii مضاد tgfb - Google Patents

الأجسام المضادة لمستقبل ii مضاد tgfb

Info

Publication number
JO3096B1
JO3096B1 JOP/2009/0382A JOP20090382A JO3096B1 JO 3096 B1 JO3096 B1 JO 3096B1 JO P20090382 A JOP20090382 A JO P20090382A JO 3096 B1 JO3096 B1 JO 3096B1
Authority
JO
Jordan
Prior art keywords
antibodies
tgf
beta receptor
rii
fibrosis
Prior art date
Application number
JOP/2009/0382A
Other languages
English (en)
Inventor
Wu Yan
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Application granted granted Critical
Publication of JO3096B1 publication Critical patent/JO3096B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير أجسام مضادة ضد مستقبل عامل النمو البشري المحول بيتا , تركيبات صيدلية تشتمل على أجسام مضادة و طرق لاستخدام الأجسام المضادة منفردة أو مجتمعة, على سبيل المثال, لعلاج السرطان و التليف.
JOP/2009/0382A 2008-11-07 2009-10-18 الأجسام المضادة لمستقبل ii مضاد tgfb JO3096B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19869708P 2008-11-07 2008-11-07
US17036909P 2009-04-17 2009-04-17

Publications (1)

Publication Number Publication Date
JO3096B1 true JO3096B1 (ar) 2017-03-15

Family

ID=41508691

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0382A JO3096B1 (ar) 2008-11-07 2009-10-18 الأجسام المضادة لمستقبل ii مضاد tgfb

Country Status (19)

Country Link
US (2) US8147834B2 (ar)
EP (1) EP2356152A1 (ar)
JP (1) JP5667067B2 (ar)
KR (1) KR101283856B1 (ar)
CN (1) CN102209727B (ar)
AR (1) AR073909A1 (ar)
AU (1) AU2009311375B2 (ar)
BR (1) BRPI0921263A2 (ar)
CA (1) CA2742961C (ar)
EA (1) EA025169B1 (ar)
IL (1) IL211842A (ar)
JO (1) JO3096B1 (ar)
MX (1) MX2011004871A (ar)
NZ (1) NZ591943A (ar)
PA (1) PA8846101A1 (ar)
SG (1) SG10201401280TA (ar)
TW (1) TWI384998B (ar)
WO (1) WO2010053814A1 (ar)
ZA (1) ZA201103178B (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150651B2 (en) * 2011-01-06 2015-10-06 Glaxo Group Limited Single variable domain immunoglobulins that bind TGF-beta receptor II
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
US20170258835A1 (en) 2014-10-31 2017-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
EP4223873A3 (en) 2015-01-31 2023-09-06 The Trustees of the University of Pennsylvania Compositions and methods for t cell delivery of therapeutic molecules
MA43186B1 (fr) * 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
PL3365368T3 (pl) 2016-03-11 2023-08-21 Scholar Rock, Inc. Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie
WO2017201527A2 (en) * 2016-05-20 2017-11-23 President And Fellows Of Harvard College Gene therapy methods for age-related diseases and conditions
AR109770A1 (es) 2016-10-18 2019-01-23 Lilly Co Eli ANTICUERPOS DEL RECEPTOR II DE TGF-b
US20180207267A1 (en) * 2017-01-06 2018-07-26 Scholar Rock, Inc. Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
CN106884005A (zh) * 2017-01-19 2017-06-23 樊克兴 一种结直肠癌抗原特异性t细胞的制备方法
JP7280254B2 (ja) 2017-10-24 2023-05-23 マジェンタ セラピューティクス インコーポレイテッド Ｃｄ１１７＋細胞を減少させるための組成物及び方法
JP2021500391A (ja) 2017-10-24 2021-01-07 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｃｄ１１７＋細胞を減少させるための組成物及び方法
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
CN107973853B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备Smad2蛋白特异性抗体的方法及其应用
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
PH12022551527A1 (en) 2019-12-24 2024-01-29 Merus Nv Tgf-beta-rii binding proteins
KR102314157B1 (ko) * 2020-01-10 2021-10-19 주식회사 뉴클릭스바이오 TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법
WO2023198194A1 (en) * 2022-04-15 2023-10-19 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-cd40 antibodies and uses thereof
CN116178567B (zh) * 2022-10-28 2025-01-28 四川大学华西医院 一种靶向TGFβRII的嵌合抗原受体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DE69232986T2 (de) * 1991-10-31 2003-12-11 Whitehead Institute For Biomedical Research, Cambridge TGF-BETA TYP III REZEPTOR, DAFüR KODIERENDE CDNS UND DEREN VERWENDUNG
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
JP2004121001A (ja) * 2002-08-07 2004-04-22 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対する高親和性モノクローナル抗体
US20090186076A1 (en) * 2006-02-01 2009-07-23 Kazunori Kataoka Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent

Also Published As

Publication number Publication date
KR101283856B1 (ko) 2013-07-15
IL211842A0 (en) 2011-06-30
TWI384998B (zh) 2013-02-11
KR20110067155A (ko) 2011-06-21
BRPI0921263A2 (pt) 2015-08-04
JP2012508170A (ja) 2012-04-05
EP2356152A1 (en) 2011-08-17
PA8846101A1 (es) 2010-06-28
EA201170659A1 (ru) 2011-10-31
CN102209727B (zh) 2014-07-30
AR073909A1 (es) 2010-12-09
WO2010053814A1 (en) 2010-05-14
JP5667067B2 (ja) 2015-02-12
US20100119516A1 (en) 2010-05-13
CA2742961A1 (en) 2010-05-14
AU2009311375B2 (en) 2014-07-31
CN102209727A (zh) 2011-10-05
TW201026326A (en) 2010-07-16
MX2011004871A (es) 2011-07-13
ZA201103178B (en) 2012-10-31
US20120177666A1 (en) 2012-07-12
SG10201401280TA (en) 2014-05-29
EA025169B1 (ru) 2016-11-30
US8147834B2 (en) 2012-04-03
IL211842A (en) 2016-09-29
AU2009311375A1 (en) 2010-05-14
CA2742961C (en) 2016-08-30
NZ591943A (en) 2012-11-30

Similar Documents

Publication Publication Date Title
JO3096B1 (ar) الأجسام المضادة لمستقبل ii مضاد tgfb
TN2011000463A1 (en) Composition and methods for increasing muscle growth
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
MX2010001378A (es) Uso terapeutico de anticuerpos del receptor anti-tweak.
TW200942551A (en) Anti-CD79b antibodies and immunoconjugates and methods of use
MX2010009743A (es) Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
MX2013004899A (es) Composicion de anticuerpos pan-her.
SG178991A1 (en) Anti-gitr antibodies
ZA200906264B (en) Aminopyrimidines useful as inhibitors of protein kinases
MX2011007930A (es) Conjugados de insulina cristalina.
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MX2010008035A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas.
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
MX2022001086A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
MX2009013082A (es) Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
MX2012006430A (es) Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide.
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
EP2294197A4 (en) HHIP1 PROTEIN VERSION AND METHOD AND USES THEREOF
MX2011013324A (es) Uso de derivados de oxindol sustituidos para el tratamiento y profilaxis del dolor.
EP2124554A4 (en) COMPOSITIONS AND METHODS FOR CANCER TREATMENT
UA101988C2 (ru) АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА II ТИПА ТРАНСФОРМИРУЮЩЕГО ФАКТОРА РОСТА БЕТА (TGFβRII)
UA104460C2 (uk) АНТИТІЛА ДО FсRCH5, ЇХ ІМУНОКОН'ЮГАТИ Й СПОСОБИ ЇХНЬОГО ЗАСТОСУВАННЯ